Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

9
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
9

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of NMR-based metabolomics and machine learning for non-invasive disease screening in dogs.

Frontiers in veterinary science·2026
Same author

Glycodeoxycholic and deoxycholic bile acids impair recognition and spatial memory in adult mice, and reduce central CREB-BDNF signaling and cytokine expression with neuroanatomical specificity.

Gut microbes·2026
Same author

Osteoarthritis pain inversely correlates with histidine and glutamine following CSF and serum profiling.

Arthritis research & therapy·2026
Same author

Therapeutic potential of stem cell-derived extracellular vesicles in aging and regeneration.

Frontiers in aging·2026
Same author

Feasibility of multimodal metabolic analysis for detecting early changes in acute neuroinflammation.

Journal of neuroinflammation·2026
Same author

Therapeutic TG2 inhibition reverses systemic multiomic dysregulation in celiac disease.

BMC medicine·2026

Related Experiment Video

Updated: Apr 23, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.3K

A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.

Alex M Dickens1, James R Larkin1, Julian L Griffin1

  • 1From the CR-UK/MRC Gray Institute for Radiation Oncology and Biology (A.M.D., J.R.L., N.R.S.), Department of Pharmacology (A.M.D., D.C.A.), Department of Chemistry (A.M.D., B.G.D., T.D.W.C.), Nuffield Department of Clinical Neurosciences (A.C., L.M., M.R.T.), and Nuffield Department of Medicine (G.K.W.), University of Oxford; and the Department of Biochemistry (J.L.G., J.P.), University of Cambridge, UK.

Neurology
|September 26, 2014
PubMed
Summary

Nuclear magnetic resonance (NMR) metabolomics can differentiate multiple sclerosis (MS) disease stages. This method accurately distinguishes relapsing-remitting MS from secondary progressive MS using serum biomarkers.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K
Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.9K

Related Experiment Videos

Last Updated: Apr 23, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.3K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K
Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.9K

Area of Science:

  • Biochemistry
  • Neuroscience
  • Medical Diagnostics

Background:

  • Multiple sclerosis (MS) is a chronic neurological disease with distinct clinical subtypes, including relapsing-remitting (RRMS) and secondary progressive (SPMS).
  • Accurate differentiation between MS subtypes is crucial for effective treatment strategies and clinical trial design.
  • Current diagnostic methods may not always clearly distinguish between different stages of MS progression.

Purpose of the Study:

  • To evaluate the efficacy of nuclear magnetic resonance (NMR) metabolomics combined with partial least squares discriminant analysis (PLS-DA) in differentiating MS disease stages.
  • To identify novel serum biomarkers for distinguishing between relapsing-remitting (RRMS) and secondary progressive (SPMS) multiple sclerosis.
  • To assess the utility of this approach in classifying patients and as an outcome measure in clinical trials.

Main Methods:

  • Serum samples were collected from patients diagnosed with primary progressive MS (PPMS), SPMS, and RRMS, alongside samples from individuals with other neurodegenerative conditions and age-matched healthy controls.
  • Nuclear magnetic resonance (NMR) spectroscopy was employed to analyze the metabolic profiles of the serum samples.
  • Partial least squares discriminant analysis (PLS-DA) models were constructed to differentiate between the various disease groups based on their metabolite profiles.

Main Results:

  • PLS-DA models successfully differentiated between RRMS and SPMS patients with high accuracy.
  • Significant differences in serum metabolite profiles were observed between each MS group (PPMS, SPMS, RRMS) and healthy controls.
  • The models demonstrated high specificity and sensitivity in predicting disease group membership.

Conclusions:

  • NMR metabolomics of serum provides a sensitive and robust method for distinguishing between different stages of MS.
  • This approach can identify diagnostic biomarkers without prior assumptions about disease mechanisms, including a validated biomarker for the RRMS to SPMS transition.
  • The findings suggest significant potential for this technique in patient stratification for treatment and as an outcome measure in future MS clinical trials.